NYSE:JNJPharmaceuticals
Johnson & Johnson (JNJ) Advances Seltorexant In Major Depressive Disorder
Johnson & Johnson (NYSE: JNJ) reports progress in its R&D pipeline, including clinical development of seltorexant for major depressive disorder.
The company advances novel antidepressant therapies alongside broader pharmaceutical initiatives.
Johnson & Johnson also signs a multi year agreement to expand access to advanced cardiac electrophysiology technologies in ambulatory surgery centers.
These moves highlight fresh momentum across both its pharmaceutical and MedTech operations, which have...